$TNFA News
Last published 1y ago
- 1y agoTNFAQCLSQ/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"Business WireLicensed technology positions Company at forefront of new quantum-class computing paradigm
- 1y agoTNFATNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic ComputingBusiness WireNew trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the
- 1y agoTNFATNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness WireTNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance
- 1y agoTNFATNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireManagement to present on Wednesday, September 10, 2025, at 8:00 a.m. ET TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced its participation in the H.C. Wainwright & Co. 27th Annual
- 1y agoTNFATNF Pharmaceuticals Announces Closing of $7 Million Private PlacementBusiness WireFinancing priced at a 44% premium to market Led by a top strategic investor with significant participation from existing stockholders TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced
- 1y agoPMCBTNFAPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsBusiness WireTNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies PharmaCyte Biotech, Inc. (NASDAQ:PMCB)
- 1y agoTNFATNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency ApplicationsBusiness WireFirst light- and laser-based computing system designed to outperform quantum and supercomputing and solve complex problems unfeasible for GPUs Strategic partner LightSolver named a 2025 World Economic Forum Technology
- 1y agoTNFATNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing ComplianceBusiness WireTNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that its
- 1y agoTNFATNF Pharmaceuticals Strengthens Financial Position for Growth and Value CreationBusiness WireTransforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage
- 1y agoTNFATNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory DiseaseBusiness WireStudy evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company
- 1y agoTNFATNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 AgonistsBusiness WireUse of AI and machine learning accelerates identification of patient groups whose care can be improved First study examines pro-inflammatory TNF-α levels in patients receiving GLP-1 agonists including Wegovy® or
- 1y agoTNFATNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug DevelopmentBusiness WireMachine learning technology used to identify patients for studies of muscle mass preservation during GLP-1 treatment TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical
- 1y agoTNFATNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025Business WirePositive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in elderly patients with
- 1y agoTNFATNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and SarcopeniaBusiness WirePositive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a
- 1y agoTNFATNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025Business WireConcurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the
- 1y agoTNFATNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha InhibitorBusiness WireFully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss and frailty Study builds on positive results achieved in earlier
- 1y agoTNFATNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss TreatmentBusiness WireSeries of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including Wegovy® or Ozempic® Lean body mass accounts for up to 40% of weight loss from GLP-1
- 1y agoTNFATNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial ExpansionBusiness WireSet to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50
- 1y agoTNFATNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss DrugsBusiness WireFully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning to identify targeted
- 1y agoTNFATNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International ConferenceBusiness WireBased on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to begin enrollment First oral TNF-α inhibitor, if approved, would offer
- 2y agoTNFATNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to MarketBusiness WirePrevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a
- 2y agoTNFATNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related DeclineBusiness WireMYMD-1® development to continue through fully funded mid-stage clinical trials Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with
- 2y agoMYMDTNFATNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open TodayBusiness WireNew name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a